• The New England Journal of Medicine has retracted the pivotal Tavneos study and, following regulatory concerns over severe liver injuries, both the FDA and European regulators have moved toward withdrawing or revoking the drug’s approval.
• This rare combination of data integrity questions and potential market rollback raises broader concerns about Amgen’s clinical governance and risk controls in rare disease development.
• We’ll now examine how the threatened withdrawal of Tavneos may reshape Amgen’s investment narrative built around innovation and diversification.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Amgen Investment Narrative Recap

To own Amgen today, you have to believe its diversified portfolio and pipeline can withstand regulatory shocks while still supporting measured revenue and earnings growth. The Tavneos controversy introduces an additional governance and compliance risk, but at Amgen’s current scale, it is unlikely to be the single most important near term earnings driver unless it signals broader clinical quality issues.

The recent European Commission approval of IMDYLLTRA for small cell lung cancer is particularly relevant here, as it highlights how Amgen’s oncology launches can offset setbacks in smaller rare disease assets like Tavneos. How regulators and clinicians respond across the portfolio will likely matter more to the medium term story than the sales loss from a single drug.

However, against this backdrop of innovation, the Tavneos withdrawal and questions over trial integrity are a reminder that investors should also be aware of...

Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029. This requires 2.5% yearly revenue growth and a $2.1 billion earnings increase from $7.8 billion today.

Uncover how Amgen's forecasts yield a $352.23 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming roughly flat revenue near US$37.1 billion and only modest earnings growth to US$7.9 billion by 2029, so you should expect that fresh Tavneos uncertainties may lead them to reassess clinical risk and governance concerns even more sharply compared with the more optimistic views.

Explore 4 other fair value estimates on Amgen - why the stock might be worth as much as 85% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 41 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.